248276-30-4

Upstream product

• 248275-92-5 11-benzyl-11-aza-tricyclo[7.3.1.02,7]trideca-2⁽⁷⁾,3,5-trien-5-ol 
• 358-23-6 trifluoromethylsulfonic anhydride 
• 248275-88-9 5-Methoxytricyclo[7.2.1.02,7]dodeca-2⁽⁷⁾,3,5,10-tetraene 
• 248275-84-5 cyclopent-3-enyl-(2,5-dimethoxy-phenyl)methanone 
• 248275-86-7 Trifluoro-methanesulfonic acid 2-(cyclopent-3-enecarbonyl)-4-methoxy-phenyl ester 
• 861220-74-8 trifluoro-methanesulfonic acid 2-(cyclopent-3-enecarbonyl)-4-hydroxy-phenyl ester 
• 248275-90-3 11-benzyl-5-methoxy-11-aza-tricyclo[7.3.1.02.7]trideca-2⁽⁷⁾,3,5-triene 
• 248275-89-0 2-methoxy-6,7,8,9-tetrahydro-5H-5,8-methano-benzocycloheptene-6,7-diol 
• 861220-61-3 cyclopent-3-enyl-(5-hydroxy-2-methoxy-phenyl)-methanone 
• 861220-87-3 2-hydroxy-5,8-dihydro-5,8-methano-benzocyclohepten-9-one 
• 248275-87-8 5-Methoxytricyclo[7.2.1.02,7]dodeca-2⁽⁷⁾,3,5,10-tetraene-8-one 

Downstream Products

• 248276-34-8 11-benzyl-11-aza-tricyclo[7.3.1.02.7]trideca-2⁽⁷⁾,3,5-triene-5-carboxylic acid methyl ester 
• 248276-36-0 2-(11-benzyl-11-aza-tricyclo[7.3.1.0^2,7]trideca-2⁽⁷⁾,3,5-trien-5-yl)-propan-2-ol 
• 248276-31-5 11-benzyl-5-(4-trifluoromethyl-phenyl)-11-aza-tricyclo[7.3.1.0^2,7]trideca-2⁽⁷⁾,3,5-triene 

Relevant academic research and scientific papers

In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: Carbon analogs of (-)-cytisine

The preparation and biological activity of analogs of (-)-cytisine, an α4β2 nicotinic receptor partial agonist, are discussed. All-carbon-containing phenyl ring replacements of the pyridone ring system, generated via Heck cyclization protocols, exhibited

Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome

This invention relates to the use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome (RLS). The invention further relates to the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The present invention also relates to a pharmaceutical composition for the treatment of RLS containing a nicotinic acetylcholine receptor agonist.

Aryl fused azapolycyclic compounds

The present invention relates to compounds of formula (I) and their pharmaceutically acceptable salts, wherein R1, R2, R3and Z are as defined herein, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders.